Investigators at Ileadbms Co. Ltd. have discovered a new cyclin-dependent kinase 12 (CDK12) and CDK13 inhibitor, IL6-110, which is being developed for the treatment of cancer.
Asgard Therapeutics AB has announced a €30 million (US$32.7 million) series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology.
There’s no denying that Johnson & Johnson’s Carvykti (ciltacabtagene autoleucel) and Bristol Myers Squibb Co.’s Abecma (idecabtagene vicleucel) show clinical benefit as they seek to move up in the line of treatment for relapsed or refractory multiple myeloma. But the question that will be put to the U.S. FDA’s Oncology Drugs Advisory Committee March 15 is whether the benefit outweighs a risk of early deaths seen with both CAR T therapies.
Nine-year-old IFM Therapeutics LLC has notched yet another big deal as Novartis AG will acquire all the outstanding capital stock of IFM Due Inc., a subsidiary of privately held IFM in an agreement that began five years ago. The newest deal brings IFM $90 million up front and makes it eligible for up to $745 million in milestone payments for a deal value of $835 million.
Recursion Pharmaceuticals LLC has described molecular glue degraders comprising DDB1- and CUL4-associated factor 15 (DCAF15) and RNA-binding protein 39 (RBM39) protein acting as RBM39 degradation inducers and RBM39/DCAF15 interaction inducers reported to be useful for the treatment of renal cell carcinoma.
Beijing Neox Biotech Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN)-targeting moiety covalently bound to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker reported to be useful for the treatment of cancer.
TET2 is a master epigenetic enzyme that converts 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), reprograming tumor cells and causing them to enter a dormant state.
RSS
